Methylene blue: what it does, and the drug interaction that matters

Reviewed 13 sourcesPublished by PepVault

Methylene blue: the approved IV use, what the brain studies measured and by how much, and why it must not be combined with SSRIs and other antidepressants.

A woman in a cobalt sweater holding a mug in both hands on a balcony
Last reviewed
Sources
13
Questions
7
Compounds
1

The short answer

Methylene blue is a blue dye and an FDA-approved IV drug for methemoglobinemia, a blood disorder. As a brain aid, one small trial found a single 280 mg dose raised correct memory answers by 7% an hour later; nothing long-term is proven. The one real risk: with SSRIs, SNRIs, MAO inhibitors or opioids it can cause serotonin syndrome, so anyone taking those checks with their prescriber first.

Every number checked at its primary source · · 13 sources · How we research

Evidence: An FDA-approved IV drug with a clear label; as a brain or longevity aid, small human trials (mostly single doses), one large negative trial of a related compound, and a mouse lifespan study with no median gain.

A woman in a cobalt sweater holding a mug in both hands on a balcony

What is methylene blue?

Methylene blue is a dye that works as a drug, and its trick is chemical: it takes electrons from one molecule and hands them to another. In the body an enzyme first converts it to leucomethylene blue, and that form turns methemoglobin back into normal hemoglobin1.

Methemoglobin is hemoglobin whose iron has been knocked into a state that cannot carry oxygen. When too much of the blood is in that state, the condition is methemoglobinemia; the acquired kind is set off by a medicine or chemical, such as the antibiotic dapsone or the industrial chemical aniline1. That is the condition the FDA approved methylene blue for, under the name ProvayBlue: 1 mg/kg intravenously over 5 to 30 minutes, with one repeat dose an hour later if the methemoglobin level stays above 30% or symptoms persist, in children and adults1.

Everything else people use it for, including small daily doses by mouth for focus or aging, is off-label: a use the label does not cover. Starting it is a decision for a doctor who knows your other medicines, for reasons the next sections make plain.

A smiling woman in a blue top leaning on her kitchen counter with her phone and a notebook

PepVault for iPhone

Keep your protocol in PepVault

PepVault logs each dose with its time and sends a reminder, so the gap since your last one is on record.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Why do people take methylene blue for the brain?

The idea comes from the same electron-passing chemistry. Mitochondria, the cell's power plants, make energy by passing electrons down a chain of proteins. The theory is that methylene blue can stand in as a backup carrier in that chain. What has been measured: in animal work, low doses raised the activity of cytochrome oxidase, the chain's last enzyme, in the brain and improved memory after learning tasks6.

Species note: the cytochrome oxidase and memory-retention findings behind the theory come from animal studies. The human results are in the next section.

One human imaging study cut the other way. In healthy volunteers given 0.5 and 1 mg/kg by IV, global brain blood flow and the brain's oxygen use both fell, the opposite of what the authors expected, and the same happened in rats10. The authors suggest the effect may depend on dose, with higher amounts slowing metabolism rather than boosting it.

What did the studies in people find?

The best single result for the brain-boost use is a 2016 trial at the University of Texas: 26 healthy adults aged 22 to 62, randomized and double-blind, 13 given one 280 mg oral dose (about 4 mg/kg) and 13 a food-colour placebo. An hour later the methylene blue group showed more fMRI activity during attention and short-term memory tasks and gave 7% more correct answers on memory retrieval (P = .01)5.

StudyWho and whatResultHow much it tells you
Rodriguez 2016526 healthy adults, one 280 mg oral dose vs placeboMore brain activity on fMRI; memory retrieval 7% better an hour laterStrongest for healthy people, but one dose, one hour, 13 per group
Telch 2014642 adults with claustrophobia (23 vs 19), one 260 mg dose right after an exposure sessionLess fear a month later when the session had gone well; a trend to more fear when it had notSmall RCT; the effect depended on how the session went
Zoellner 2017742 adults with PTSD in 3 arms (one a waitlist), 260 mg after each of 5 daily exposure sessionsBoth groups improved; methylene blue raised the response rate (1 extra responder per 7.5 treated) and quality of life over placeboSmall RCT, preliminary
Alda 2017837 adults with bipolar disorder, 195 mg vs 15 mg a day, 3 months on eachDepression and anxiety improved; cognition did notSmall crossover trial, an add-on to lamotrigine
Deng 20219248 older adults, 2 mg/kg IV during major surgeryDelirium 7.3% vs 24.2%; early cognitive problems 16.1% vs 40.2%Larger, but open-label and a hospital setting
Gauthier 201611891 people with mild to moderate Alzheimer disease, LMTM for 15 months against a low-dose controlNo benefit on memory or daily functionLarge phase 3, negative; LMTM is a related compound
Harrison 201412Genetically mixed mice, in the diet from 4 months of ageNo change in median lifespan; female maximum lifespan +6%Mice, not people

Read together: methylene blue has a measurable short-run effect on memory in small trials, and the cleanest human data is for a single dose. The surgical delirium trial is the biggest effect in the table, by IV in a hospital. The one large long-term trial, of the related tau drug LMTM, failed11, and the mice in the National Institute on Aging's lifespan program did not live longer on it on average12. None of these trials tested small daily oral doses for aging.

Commonly reported: users describe a clearer head and steadier focus within an hour or two of a dose, and blue or green urine the same day.

Can you take methylene blue with an SSRI?

No, by the label. ProvayBlue's boxed warning, the box at the top of the label, says it may cause serious or fatal serotonin syndrome with serotonin-acting drugs and opioids, and to avoid it with SSRIs, SNRIs, MAO inhibitors and opioids1. The drug interactions section adds bupropion, buspirone, clomipramine, mirtazapine, linezolid and dextromethorphan1.

The reason: methylene blue is a potent, reversible MAO inhibitor. It blocks monoamine oxidase A, the enzyme that breaks down serotonin, so beside a drug that already raises serotonin the level can climb into toxicity12. Serotonin syndrome means agitation or confusion, a racing heart, sweating, fever, tremor, muscle twitching or stiffness, and sometimes seizures12.

The FDA warned about this in July 20112. A review of the published cases found 26 patients who became acutely confused after a methylene blue infusion; 24 were on a serotonin reuptake inhibitor and one on clomipramine4. Most FDA reports came from parathyroid surgery, at IV doses of 1 to 8 mg/kg. Whether IV doses under 1 mg/kg, or doses by mouth, carry the same risk is not known, the FDA said3. The memory trial's single dose, about 4 mg/kg by mouth, falls in the same mg/kg range as those reports, and that trial excluded anyone who had taken psychiatric medicine in the past 5 weeks5.

The timing ruleWhat it saysSource
After a dose of methylene blueNo serotonergic drugs for 72 hoursProvayBlue label1
Before planned methylene blueMost serotonergic psychiatric drugs stopped at least 2 weeks ahead; fluoxetine at least 5 weeksFDA, 20112
Restarting the antidepressantNot before 24 hours after the last methylene blueFDA, 20112

Those windows are written for doctors planning a procedure, not for a self-run washout. The FDA's advice to patients is plain: never stop an antidepressant without your prescriber, and make sure they know every medicine you take2.

When to get help If confusion, a racing heart, heavy sweating, fever, shaking or muscle stiffness start after methylene blue while you take an antidepressant, migraine medicine or an opioid, get medical help straight away12.

Who else should not take methylene blue?

  • People with G6PD deficiency. G6PD is an enzyme that protects red blood cells; without enough of it, methylene blue can cause severe hemolysis (red cells breaking apart) and severe anemia. The label makes it a contraindication, a firm no1.
  • Anyone with a severe allergy to methylene blue or another thiazine dye1.
  • Pregnancy and breastfeeding. The label says it may harm a fetus and advises stopping breastfeeding for up to 8 days after a dose1.
  • Reduced kidney function. Blood exposure rose 52%, 116% and 192% in mild, moderate and severe kidney impairment1.

Two quieter effects worth knowing: methylene blue in the blood makes a pulse oximeter read oxygen lower than it is, and it can cause confusion, dizziness or blurred vision, so the label advises against driving until those pass1.

Why does methylene blue turn urine blue?

Because it is a dye, and it leaves the body largely through the kidneys: about 40% comes out in the urine unchanged1. Blue or green urine is expected and harmless. In the memory trial, everyone given methylene blue reported blue urine and no one on placebo did5. The label also notes blue colour in the skin and other body fluids, and that it can throw off urine dipstick tests that read a blue colour, so mention it before one1.

In the approved hospital use, the effects reported in 2% or more of the 31 adults treated in its studies were headache, low potassium, diarrhea, low magnesium, muscle jerks, nausea and seizure-like events1. The label also advises protecting skin from light after a dose, since it can make skin react to light1.

How long does methylene blue stay in your body?

About a day per half. The label gives a half-life of about 24 hours1, so roughly half a dose is still in the blood a day later and about an eighth after three days, the span of the label's 72-hour window. Taken by mouth, about 72% of a dose reaches the bloodstream, against an IV dose13.

Try it

How Methylene Blue builds up

An estimate from a half-life of about 24 hours, one dose a day for four weeks. The shape of the level, not a measurement.

Try your own scheduleMethylene Blue in the library

  • A daily dose builds on the one before: with a 24-hour half-life, the level climbs for several days before it levels off.

PepVault logs each dose with its time and sends a reminder, so the gap since your last one is on record. Set reminders in PepVault

Its side-effect log keeps what you noticed and when, to show the prescriber who signs off on it. Log it in PepVault

Track it in the app

Sources

  1. ProvayBlue (methylene blue) injection, prescribing information, American Regent. DailyMed setid 4f6848e5-35ed-4046-b13c-3032b5ba3232, version 28, Jun 2025. dailymed.nlm.nih.gov
  2. FDA Drug Safety Communication: Serious CNS reactions possible when methylene blue is given to patients taking certain psychiatric medications. July 26, 2011. web.archive.org
  3. FDA Drug Safety Communication: Updated information about the drug interaction between methylene blue and serotonergic psychiatric medications. October 20, 2011. web.archive.org
  4. Ng BK, Cameron AJ. The role of methylene blue in serotonin syndrome: a systematic review. Psychosomatics. 2010. PubMed 20484716
  5. Rodriguez P et al. Multimodal randomized functional MR imaging of the effects of methylene blue in the human brain. Radiology. 2016. PubMed 27351678
  6. Telch MJ et al. Effects of post-session administration of methylene blue on fear extinction and contextual memory in adults with claustrophobia. Am J Psychiatry. 2014. PubMed 25018057
  7. Zoellner LA et al. Enhancing extinction learning in posttraumatic stress disorder with brief daily imaginal exposure and methylene blue: a randomized controlled trial. J Clin Psychiatry. 2017. PubMed 28686823
  8. Alda M et al. Methylene blue treatment for residual symptoms of bipolar disorder: randomised crossover study. Br J Psychiatry. 2017. PubMed 27284082
  9. Deng Y et al. Methylene blue reduces incidence of early postoperative cognitive disorders in elderly patients undergoing major non-cardiac surgery: an open-label randomized controlled clinical trial. J Clin Anesth. 2021. PubMed 33091706
  10. Singh N et al. The effects of acute methylene blue administration on cerebral blood flow and metabolism in humans and rats. J Cereb Blood Flow Metab. 2023. PubMed 36803299
  11. Gauthier S et al. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet. 2016. PubMed 27863809
  12. Harrison DE et al. Acarbose, 17-alpha-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males. Aging Cell. 2014. PubMed 24245565
  13. Walter-Sack I et al. High absolute bioavailability of methylene blue given as an aqueous oral formulation. Eur J Clin Pharmacol. 2009. PubMed 18810398

Newsletter · Weekly

The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

We’ll email you a link to confirm. Your address is used for the briefing only. Privacy

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo